BRIEF-Immunovaccine posts positive early stage trial results of DPX-survivac in ovarian cancer
Aug 25 (Reuters) - Immunovaccine Inc:
* Immunovaccine announces additional positive top-line results from phase 1/1b clinical trial program with DPX-survivac in ovarian cancer
* Trial had no unexpected treatment-related serious adverse events Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.